Explore stories from Atlantic Canada.
Cooking Culinary Adventure: inspired by Halifax's Seaport Market | SaltWire #cooking #cookingshortsSHANGHAI - Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials.Representatives for Merck did not immediately respond to a Reuters request for comment.
The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm. Merck is aiming for at least $6 billion in revenue from its oncology business in the fiscal year ending March 31, 2026, which would represent about a five-fold increase over a three-year period.
The co-developed drug candidates belonged to a class known as antibody drug conjugates , which unlike conventional chemotherapy are designed to target only cancer cells, potentially reducing damage to normal cells. Cooperation with Merck on seven other ADC candidates - three in clinical trials - was unaffected, Kelun said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Merck discontinues some cancer drug development with China's Sichuan KelunExplore stories from Atlantic Canada.
Lire la suite »
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo DealMerck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech after clinching a pact with Japan’s Daiichi Sankyo Co., dealing a fresh blow to companies in China seeking to prove their chop in developing innovative cancer therapies.
Lire la suite »
Philippines labels China as an 'aggressor' fanning tensions in the South China SeaExplore stories from Atlantic Canada.
Lire la suite »
Philippines tells China to stop provocative actions in South China SeaExplore stories from Atlantic Canada.
Lire la suite »
Philippines tells China to stop provocative actions in South China SeaExplore stories from Atlantic Canada.
Lire la suite »
Merck, Seagen Drug Cocktail Seen as New Bladder Cancer StandardMerck & Co. and Seagen Inc.’s drug cocktail is set to replace chemotherapy as a first choice for bladder cancer patients, doctors said, the first alternative to the toxic treatment in 30 years.
Lire la suite »